Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
Executive Summary
Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.
You may also be interested in...
Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price
But Novo Nordisk CEO says a DEVOTE-based efficacy price review in Germany analyzing patient sub-groups 'will be a lengthy process'.
Can Sanofi’s Toujeo Prickle Tresiba In India?
Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.
ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity
The high cost of basal insulins in the US has drawn a fair amount of scrutiny recently, placing increased pressure on new longer acting insulins to demonstrate superior cost-efficacy compared to standard of care Lantus to gain preferential formulary placement. This has become significantly more difficult with the US launch of Lilly's biosimilar, Basaglar.